Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Denosumab + pamidronate + Zoledronic acid |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Denosumab | Xgeva | AMG162|AMG-162|AMG 162|Prolia | Xgeva (denosumab) is an antibody that binds to RANKL protein, inhibiting osteoclast activity and is FDA approved for use in patients with giant cell tumor of the bone (FDA.gov). | |
Zoledronic acid | Zometa | zoledronate | ||
pamidronate | Aredia | GCP-23339A |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02721433 | FDA approved | Denosumab + pamidronate + Zoledronic acid | 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA) | Completed | CAN | 0 |